Recent

% | $
Quotes you view appear here for quick access.

Titan Pharmaceuticals Inc. Message Board

pechstein.carl 15 posts  |  Last Activity: Jul 28, 2016 8:46 AM Member since: Oct 22, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • "The current system does not provide comprehensive treatment as defined by the American Society of Addiction Medicine (ASAM) criteria. In addition, it suffers from both fragmentation and stigma and will require a significant change to comply with ASAM's call for integrated delivery of comprehensive addiction treatment. This commentary calls for the development and implementation of “best practice,” by recommending caution in lifting the 100 patient limit until substantial achievement of this goal occurs. The authors call for an increase to 200 in the patient limit to be restricted to those physicians who are Board Certified in Addiction Medicine by the American Board of Addiction Medicine (ABAM) or in Addiction Psychiatry by the American Board of Psychiatry and Neurology (ABPN), or other responsible medical organizations. Any additional restriction lifting should follow a systemic evolution that rewards and documents competency. Such a system would involve the integration of treatment, treatment systems, and recovery with prescription medication. In addition, it should monitor emotional blunting, treatment progress and initiation of genetic addiction risk testing."
    Author affiliations:
    a Department of Psychiatry & McKnight Brain Institute, University of Florida College of Medicine, Gainesville, Florida, USA
    b Division of Addiction Services, Dominion Diagnostics, LLC, North Kingstown, Rhode Island, USA
    c Division of Neuroscience-Based Therapy, Summit Estate Recovery Center, Los Gatos, California, USA
    d Departments of Psychiatry & Behavioral Sciences, Keck School of Medicine of USC, Los Angeles, California, USA
    e Division of Neuroscience Research & Addiction Therapy, Shores Treatment & Recovery Center, Port Saint Lucie, Florida, USA
    f Department of Clinical Neurology, PATH Foundation NY, New York, New York, USA
    g Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA
    h Public Health Program, Santa

  • pechstein.carl pechstein.carl Jul 28, 2016 7:33 AM Flag

    i think so.

  • pechstein.carl pechstein.carl Jul 27, 2016 3:32 PM Flag

    it is only conditionally approved for a very small segment of addicts and only for up to one year. then they must go back to the film or the patch. that is how it is approved. the notion that it will be widely accepted is unfounded and premature. while the pumpers expect an ovation with strong market penetration, it is not going to happen.

  • Aside from risk of addiction, perhaps the most distressing impact of Buprenorphine is the fact that it does nothing to treat the underlying causes of addiction. According to Serenity Recovery Center, “As the United States continues to experience epidemic levels of Opiate addiction, the prescribing practices may be a function of ease. In other words, to keep up with the increasing number of addicted patients, doctors turn to drugs like Buprenorphine as a quick, easy, and cheap treatment option.”

    Unfortunately, this option comes with several risks. When the underlying causes of addiction, such as mental health issues or previous trauma, are not addressed during treatment, it will do nothing to help an addict achieve long-term recovery. Serenity, therefore, is committed to providing patients with holistic, natural, and drug-free substance abuse treatment options. With this information provided by Serenity Recovery Center, individuals who are seeking treatment for substance abuse issues can truly understand the nature of Buprenorphine and the potential consequences of its use. They will also learn about the holistic treatment options that are designed to treat the mind, body, and soul, without the use or introduction of additional harmful chemicals.

    While Buprenorphine has been proven to reduce drug cravings in individuals who are struggling with addiction to Opiates, it is important to remember that it also comes with a risk of addiction and side effects including seizures, difficulty breathing, vomiting, and cognitive impairment. With these new regulations, more addicts will be subjected to the potentially hazardous consequences associated with Buprenorphine. Holistic treatment options, however, are designed to restore an addict’s natural bodily functions, so he or she can resolve any underlying issues that may have contributed to substance abuse. When drugs are used to treat substance abuse, it can only cause further disruption of a patient’s mind, body, and soul,

  • pechstein.carl pechstein.carl Jul 27, 2016 11:21 AM Flag

    how can they claim it is non-inferior when stable patients relapsed when switched to the implant? pumpers have all slithered back under their rocks while the real peer reviews is looming, waiting to reveal the truth.

  • Every once in a while, the course of history is traversed and consequently transfigured by certain individuals, whose spectacular brilliance dazzles their contemporaries, brightens up the world around them and blazes a trail of excellence for those coming after them. The rarity of such luminaries lies not just in the enormity of their impact but in its far-reaching diversity. As I write, the pharmaceutical world and indeed the scientific world is witnessing the revolutionising impact of one of such pacesetters.

    Meet Prof. Isa Odidi, the erudite pharmacist, celebrated scientist, distinguished innovator, first-rate technocrat and consummate entrepreneur, whose foremost passion is bridging the worlds of design, science, technology, innovation and entrepreneurship, with a view to maximising the outcome for economic and social advancement in developing economies such as Nigeria.

    With over 100 issued and pending patents in the USA, Canada and other international jurisdictions, Prof. Odidi is globally recognised as a prolific inventor in pharmaceutics and pharmaceutical technology. He is acclaimed for pioneering controlled, targeted or timed release drug delivery technologies and their “reduction to practice” to allow commercialisation and use for the common good. A tireless researcher, his works have been cited in several publications and he has published over a hundred scientific and medical papers, articles and textbooks.

  • pechstein.carl pechstein.carl Jul 26, 2016 3:47 PM Flag

    it fall under PA prior authorization. that means that other formulas must have failed. you being in the med. profession doesn't change the definition of PA.

  • pechstein.carl pechstein.carl Jul 20, 2016 9:13 AM Flag

    i've never heard a company use a pitch like that. unusual payment models sounds like something out of enron or the mortgage disaster. why do they need to use unusual payments methods? what's wrong with traditional payment methods? do they accept bitcoins?

  • Reply to

    Jama publication today

    by timeout1833 Jul 19, 2016 3:42 PM
    pechstein.carl pechstein.carl Jul 20, 2016 6:24 AM Flag

    cherry picking,,,lol i haven't started yet pumptard. just wait for the dreaded peer review next week. this junk science study has more holes than a slice of swiss cheese. they didn't test for anything but "illicit opiates". the participants had 3-5 years of prior MAT. the results contradict their own prior study as well as others. did you notice the Indivior investigator on the team? you are so stupid,,,go buy more.

  • Reply to

    Jama publication today

    by timeout1833 Jul 19, 2016 3:42 PM
    pechstein.carl pechstein.carl Jul 19, 2016 6:42 PM Flag

    "A limitation of this study was that it was not powered to detect differences in adverse outcomes. "
    that means that their sensitivity methods were lacking sense. no wonder they all keep talking about additional trials.

  • pechstein.carl pechstein.carl Jul 12, 2016 9:53 AM Flag

    not everyone who drives under the influence is impaired. that is when the doc will be held liable imo. i don't think alcohol was considered a failure in the trial, but yet there is warning about alcohol and benzos when mixed with bupe.

  • pechstein.carl pechstein.carl Jul 12, 2016 6:54 AM Flag

    In total, the managed care plan that BDSI has contracted with covers in excess of 10.5 million lives and has provided coverage for an estimated more than 140,000 prescriptions over the last 12 months for buprenorphine products for opioid dependence for which the market leader has a majority, according to data from Symphony Health. The agreement officially goes into effect on January 1, 2017, although BDSI anticipates that healthcare providers may begin to make the transition prior to that date.

  • As a result of the agreement, access to BUNAVAIL will be improved substantially from its current non-formulary position with this managed care plan to a preferred formulary position, while the current market leader is made non-preferred. The other branded buprenorphine/naloxone product will share preferred status with BUNAVAIL.

    Agreement provides BUNAVAIL with an opportunity to access a significant portion of more than 140,000 additional prescriptions annually.

  • pechstein.carl pechstein.carl Jul 6, 2016 3:46 PM Flag

    it isn't irrelevant, in fact it explains the sp movement down. no need to question my track record, just look at a 20 year chart. read the pumper post about how braeburn is going to share profits from camurus with titan. he has a whole story about braeburn's plan to transition patients from the injections to the implant. it's absolutely hysterical. the price action speaks for itself. and so yes, i guess i am the only one who can see as the sp just broke through the 100dma in a bearish manner.

  • pechstein.carl pechstein.carl Jul 6, 2016 12:08 PM Flag

    what does is have to do with anything? they directly mention titan. i know you would rather hear about all the glory and profits that will come from your socially responsible investment, but you have been had. there is nothing left, and soon there will be less than nothing.

TTNP
4.96-0.08(-1.59%)Jul 29 4:00 PMEDT